Where Cannabinoids Fit in Contemporary Chronic Pain Management: Evidence-Based Review

Chronic pain remains one of the most difficult conditions to manage in clinical practice, especially for patients who have inadequate response or intolerance to first-line therapies. Emerging data continues to evaluate cannabinoids as potential adjunctive therapies in select chronic pain populations, particularly in patients with limited treatment options. While there has been a significant increase in interest, the current data indicates a more limited and condition-specific role than widespread substitution for standard analgesics.¹

Chronic Pain Management and Treatment Positioning

Generally, guideline-directed therapy for chronic pain prioritizes nonpharmacologic interventions and first-line pharmacologic agents depending on pain subtype. Options such as gabapentinoids, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants remain foundational for neuropathic pain.² In nociceptive pain, acetaminophen, NSAIDs, and select adjuvant therapies are commonly used, while opioid therapy is reserved for refractory cases due to safety concerns and dependence risk.

Cannabinoids—primarily delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)—are a main focus of research as adjunctive therapies rather than replacements for established pain management approaches, including nonpharmacologic interventions, NSAIDs, antidepressants, gabapentinoids, and other guideline-recommended treatments. Their proposed mechanism involves modulation of the endocannabinoid system, particularly through CB1 and CB2 receptor activity, which plays an important role in regulating pain perception, inflammatory responses, and central pain processing.³

Mechanism of Action

The endocannabinoid system plays a regulatory role in pain perception, immune response, and neurotransmitter release. THC behaves as a partial agonist at CB1 receptors in the central nervous system, contributing to analgesia but also psychoactive effects. In contrast, CBD has low affinity for cannabinoid receptors but is considered to modulate inflammatory pathways and receptor signaling indirectly.³

Preclinical data indicate potential benefit in neuropathic pain models and inflammatory states; however, translation to consistent clinical efficacy has been limited due to heterogeneity in formulations, dosing, and study design.^3,4 This variability remains one of the key barriers to definitive conclusions.

Evidence in Chronic Pain Conditions

Mixed results have been reported in systematic reviews and meta-analyses evaluating cannabinoids in chronic pain. Research published in JAMA concluded that there is “substantial evidence” that supports cannabis or cannabinoids for chronic pain in adults, though the magnitude of benefit is generally modest.⁴ Systematic reviews and meta-analyses evaluating cannabinoids for chronic pain have generally demonstrated modest improvements in pain outcomes, although the overall magnitude of benefit remains limited.⁴⁻⁶

Evidence appears most promising in:

• Neuropathic pain: Data demonstrates small-to-moderate reductions in pain scores, particularly with nabiximols (THC/CBD oromucosal spray).⁵
• Multiple sclerosis–related spasticity and pain: Cannabinoid-based therapies have demonstrated improvement in patient-reported spasticity and sleep disruption.⁶
• Cancer-related pain: Although cannabinoids have been investigated as adjunctive therapies, evidence supporting their use remains inconsistent, and their role in cancer-related pain management has yet to be clearly established.⁴⁻⁶

Despite these findings, the generalizability of the available evidence is limited by methodological challenges, including small sample sizes, short follow-up durations, and variability in cannabinoid formulations.⁴⁻⁶ Current evidence supports cannabinoids as adjunctive therapy in select refractory cases rather than a primary analgesic option.

Safety Limitations

Cannabinoid therapy is associated with a distinct adverse effect profile, which includes dizziness, sedation, cognitive impairment, and psychiatric effects such as anxiety or paranoia, particularly with THC-dominant products.⁴ Drug–drug interactions are also clinically relevant, particularly via cytochrome P450 enzyme modulation, which may affect commonly used analgesics, antidepressants, and anticonvulsants.³⁻⁵ Long-term safety data for cannabinoids remain limited, particularly in older adults and patients with cardiovascular or psychiatric comorbidities.⁴⁻⁶ Additionally, variability in product composition across jurisdictions complicates reproducibility, dosing consistency, and generalizability of findings.^1,4-6

REFERENCES

1. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids. Washington, DC: The National Academies Press; 2017. Accessed June 8th, 2026. https://www.nationalacademies.org/read/24625/chapter/1

2. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0

3. Pertwee, R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30(Suppl 1), S13–S18 (2006). https://doi.org/10.1038/sj.ijo.0803272

4. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358

5. Häuser, Winfried & Petzke, Frank & Fitzcharles, M.‐A. (2017). Efficacy, tolerability and safety of cannabis‐based medicines for chronic pain management – An overview of systematic reviews. European Journal of Pain. 22. 10.1002/ejp.1118. Accessed June 8th, 2026.

6. Ateş G, Welsch P, Klose P, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2026;1(1):CD012182. Published 2026 Jan 19. doi:10.1002/14651858.CD012182.pub3. Accessed June 8th, 2026